home / stock / torc / torc quote
Last: | $2.28 |
---|---|
Change Percent: | -3.8% |
Open: | $2.38 |
Close: | $2.28 |
High: | $2.46 |
Low: | $2.21 |
Volume: | 850,283 |
Last Trade Date Time: | 09/15/2020 04:55:40 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.28 | $2.38 | $2.28 | $2.46 | $2.21 | 850,283 | 09-15-2020 |
$2.37 | $2.14 | $2.37 | $2.39 | $2.14 | 712,328 | 09-14-2020 |
$2.15 | $2.13 | $2.15 | $2.19 | $2.06 | 211,501 | 09-11-2020 |
$2.11 | $2.11 | $2.11 | $2.18 | $2.03 | 171,517 | 09-10-2020 |
$2.09 | $2 | $2.09 | $2.15 | $2 | 229,857 | 09-09-2020 |
$1.97 | $2 | $1.97 | $2.06 | $1.92 | 221,406 | 09-08-2020 |
$2 | $2.06 | $2 | $2.08 | $1.882 | 453,652 | 09-07-2020 |
$2 | $2.06 | $2 | $2.08 | $1.882 | 453,541 | 09-04-2020 |
$2.08 | $2.18 | $2.08 | $2.2 | $2.045 | 240,002 | 09-03-2020 |
$2.17 | $2.12 | $2.17 | $2.2 | $2.09 | 186,467 | 09-02-2020 |
$2.13 | $2.29 | $2.13 | $2.3 | $2.1 | 278,186 | 09-01-2020 |
$2.28 | $2.05 | $2.28 | $2.3 | $2.05 | 605,573 | 08-31-2020 |
$2.05 | $2.03 | $2.05 | $2.13 | $2.03 | 244,363 | 08-28-2020 |
$2.05 | $2.16 | $2.05 | $2.1792 | $2.02 | 151,733 | 08-27-2020 |
$2.15 | $2.06 | $2.15 | $2.21 | $2.02 | 211,264 | 08-26-2020 |
$2.05 | $2.03 | $2.05 | $2.11 | $2.02 | 314,847 | 08-25-2020 |
$2.08 | $2.17 | $2.08 | $2.18 | $2.02 | 510,825 | 08-24-2020 |
$2.19 | $2.3 | $2.19 | $2.34 | $2.14 | 313,353 | 08-21-2020 |
$2.27 | $2.15 | $2.27 | $2.3 | $2.15 | 246,874 | 08-20-2020 |
$2.17 | $2.23 | $2.17 | $2.29 | $2.16 | 387,429 | 08-19-2020 |
News, Short Squeeze, Breakout and More Instantly...
- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on The Nasdaq Global Market Under Ticker Symbol “ACET”- MENLO PARK, Calif. and BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -...
MENLO PARK, Calif. , Aug. 5, 2020 /PRNewswire/ -- Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that it has received a $10 million milestone payment from Regeneron associated with ADI-002 meeting key preclinical development goals, in accordance with the t...
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results ...